Please assess the completion status of the following clinical trial:

Trial Title: Study of Bictegravir/Emtricitavine/Tenofovir Alafenamide in HIV-1 Infected naïve Patients Using Test and Treat Stategy Rapid-initiation Model of Care: BIC-NOW Clinical Trial (BIC-NOW)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. HIV-1 infected adults (\>17 y.o.)~2. Antiretroviral-naïve.~3. Be able to comply with protocol requirements and instructions.~4. Subject or the subject's representative capable of giving signed informed consent~Exclusion Criteria:~1. Women who are breastfeeding or plan to become pregnant during the study.~2. Patients who in the investigator's judgment, poses a significant drop out risk or life expectancy inferior to study ending.~3. Patients with anticipated need to change the ART before study ending.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- study group (Type: EXPERIMENTAL): HIV-1 infected adults, ART-naive subjects, who start BIC/FTC/TAF using test and treat strategy recruited at infectious diseases units from various Spanish public healthcare centers.

Based on this trial design, predict the completion outcome and termination type (if applicable).